Antineutrophil Cytoplasmic Antibody-Positive Small-Vessel Vasculitis Associated with Antithyroid Drug Therapy: How Significant Is the Clinical Problem

Thyroid

Volumn 25, Issue 12, 2015, Pages 1273-1281

  Balavoine, Anne Sophie ^a   Glinoer, Daniel ^b   Dubucquoi, Sylvain ^a   Wémeau, Jean Louis ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPYLTHIOURACIL; THIAMAZOLE; THIOURACIL DERIVATIVE;

AGE; ANCA ASSOCIATED SMALL VESSEL VASCULITIS; ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; CARDIOVASCULAR RISK; CLINICAL FEATURE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAVES DISEASE; HUMAN; MICROSCOPIC POLYANGIITIS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMALL VESSEL VASCULITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; HYPERTHYROIDISM; TIME FACTOR;

AGE FACTORS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTITHYROID AGENTS; HUMANS; HYPERTHYROIDISM; METHIMAZOLE; PREVALENCE; PROPYLTHIOURACIL; TIME FACTORS;

EID: 84951944351     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2014.0603     Document Type: Review

References (62)

1. Astwood EB, Vanderlaan WP 1946 Treatment of hyperthyroidism with propylthiouracil. Ann Intern Med 25:813-821.
2. Poate H 1953 Thyrotoxicosis treated with 2-carbethoxythio-1-methylglyoxaline (neo mercazole). Lancet 1:879-881.
3. Cooper DS 2005 Antithyroid drugs. N Engl J Med 352: 905-917.
4. Borson-Chazot F, Caron P, Glinoer D, Wémeau JL 2014 Antithyroid drugs: what kind of prescription Presse Med 43:105-108.
5. Glinoer D, Cooper DS 2012 The propylthiouracil dilemma. Curr Opin Endocrinol Diabetes Obes 19:402-407.
6. Dolman KM, Gans RO, Vervaat TJ, Zevenbergen G, Maingay D, Nikkels RE, Donker AJ, von dem Borne AE, Goldschmeding R 1993 Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 342:651-652.
7. Vogt BA, Kim Y, Jennette JC, Falk RJ, Burke BA, Sinaiko A 1994 Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 124:986-988.
8. Mouthon L, Millet A, Regent A, Pederzoli-Ribeil M, Witko-Sarsat V 2012 Pathophysiology of ANCA-associated vasculitides. Presse Med 41:996-1003.
9. Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, McEvoy R, Pusey C, Pollock W, Trevisin M, Wiik A, Wong R 2003 International Group for Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 120:312-318.
10. Tsiveriotis K, Tsirogianni A, Pipi E, Soufleros K, Papasteriades C 2011 Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected Greek patients. Autoimmune Dis 2011:626495.
11. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, Lesavre P, Lüdemann J, Rasmussen N, Sinico RA, Wiik A, van der Woude FJ 1998 Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 53:743-753.
12. Csernok E, Holle JU 2010 Twenty-eight years with antineutrophil cytoplasmic antibodies (ANCA): how to test for ANCA-evidence-based immunology Auto Immun Highlights 1:39-43.
13. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Lugmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA 2013 2012 Revised International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides. Arthritis Rheum 65:1-11.
14. Choi HK, Merkel PA, Walker AM, Niles JL 2000 Drugassociated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 43:405-413.
15. Merkel PA 1998 Drugs associated with vasculitis. Curr Opin Rheumatol 10:45-50.
16. Ten Holder SM, Joy MS, Falk RJ 2002 Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 36:130-147.
17. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A 2000 Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 142:587-590.
18. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, Miyamoto S 2000 High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 85:4270-4273.
19. Sera N, Ashizawa K, Ando T, Abe Y, Ide A, Usa T, Tominaga T, Ejima E, Yokoyama N, Eguchi K 2000 Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 10:595-599.
20. Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, Abe Y, Ito K, Ito K 2001 Frequency of appearance of myeloperoxydaseantineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf) 54:651-654.
21. Wada N, Mukai M, Kohno M, Notoya A, Ito T, Yoshioka N 2002 Prevalence of serum anti-myeloperoxydase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. Endocr J 49:329-334.
22. Huang CN, Hsu TC, Chou HH, Tsay GJ 2004 Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan. J Formos Med Assoc 103:274-279.
23. Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, Savage CO, Franklyn JA 2004 Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf) 60:671.
24. Gao Y, Zhao MH, Guo XH, Xin G, Gao Y, Wang HY 2004 The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic autoantibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr Res 30:205-213.
25. Slot MC, Links TP, Stegeman CA, Tervaert JW 2005 Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long-term follow up study. Arthritis Rheum 53:108-113.
26. Panamonta O, Sumethkul V, Radinahmed P, Laopaiboon M, Kirdpon W 2008 Propylthiouracil associated antineutrophil cytoplasmic antibodies (ANCA) in patients with childhood onset Graves' disease. J Pediatr Endocrinol Metab 21:539.
27. Yazisiz V, Ongüt G, Terzioglu E, Karayalçin U 2008 Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment. Int J Clin Pract 64:19.
28. Chen LQ, Zhang XL, Wu HY, Guo S, Li XZ 2008 Relationship between methimazole and antineutrophil cytoplasmic antibody-positive vasculitis. Zhonghua Er Ke Za Zhi 46:446.
29. Sghiri R, Ouertani M, Ben Hsine H, Slim I, Chaieb L, Ghedira I 2009 Prevalence of antineutrophil cytoplasmic antibodies during treatment with benzylthiouracil. Pathol Biol (Paris) 57:410-414.
30. Cin MO, Gursoy A, Morris Y, Aydintug OT, Kamel N, Gullu S 2009 Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil. Int J Clin Pract 63:299-302.
31. Kobayashi S, Fujimoto S 2013 Epidemiology of vasculitides: differences between Japan, Europe and North America. Clin Exp Nephrol 17:611-614.
32. Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, Manji N, Allahabadia A, Armitage M, Chatterjee KV, Lazarus JH, Pearce SH, Vaidya B, Gough SC, Franklyn JA 2010 Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 123:183.e1-9.
33. Kahaly GJ 2012 Polyglandular autoimmune syndrome type 2. Presse Med 41:e663-670.
34. Wémeau JL, Proust-Lemoine E, Ryndak A, Vanhove L 2013 Thyroid autoimmunity and polyglandular endocrine syndromes. Hormones (Athens) 12:39-45.
35. Guma M, Salinas I, Reverter JL, Roca J, Valls-Roc M, Juan M, Olivé A 2003 Frequency of antineutrophil cytoplasmic antibody in Graves' disease patients treated with methimazole. J Clin Endocrinol Metab 88:2141-2146.
36. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Jennette JC, Nachman PH 2007 Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant 22:3508-3515.
37. Noh JY, Yasuda S, Sato S, Matsumoto M, Kunii Y, Noguchi Y Mukasa K, Ito K, Ito K, Sugiyama O, Kobayashi H, Nihojima S, Okazaki M, Yokoyama S 2009 Clinical characteristics of myeloperoxydase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab 94:2806-2811.
38. Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M 2005 Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune disease induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 7:R1072-1081.
39. Mandl LA, Solomon DH, Smith EL, Lew RA, Katz JN, Shmerling RH 2002 Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy Arch Intern Med J 162:1509-1514.
40. Lim LC, Taylor JG 3rd, Schmitz JL, Folds JD, Wilkman AS, Falk RJ 1999 Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology. Comparative evalua-tion of commercial indirect fluorescent antibody kits and enzyme immunoassay kits. Am J Clin Pathol 111:363-369.
41. Rivkees SA, Szarfman A 2010 Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 95:3260-3267.
42. Haubitz M, Woywodt A, de Groot K, Haller H, Goebel U 2005 Smoking habits in patients diagnosed with ANCA associated small vessel vasculitis. Ann Rheum Dis 64: 1500-1502.
43. Ishii R, Imaizumi M, Ide A, Sera N, Ueki I, Horie I, Ando T, Usa T, Ejima E, Ashizawa K, Eguchi K 2010A long-term follow-up of serum myeloperoxydase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves disease treated with propylthiouracil. Endocr J 57:73-79.
44. Wang C, Gou SJ, Xu PC, Zhao MH, Chen M 2013 Epitope analysis of anti-myeloperoxidase antibodies in propylthiouracilinduced antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther 15:R196.
45. Chen YX, Zhang W, Chen XN, Yu HJ, Ni LY, Xu J, Pan XX, Ren H, Chen N 2012 Propylthiouracil-induced antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis versus primary ANCA-associated renal vasculitis: a comparative study. J Rheumatol 39:558-563.
46. Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH 2008 Long-term outcomes of patients with propylthiouracilinduced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatology (Oxford) 47:1515-1520.
47. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B 1999 Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42:421-430.
48. Chung SA, Seo P 2010 Microscopic polyangiitis. Rheum Dis Clin North Am 36:545-558.
49. Clain JM, Cartin-Ceba R, Fervenza FC, Specks U 2014 Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Ther Adv Musculoskelet Dis 6:58-74.
50. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumâtre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quemeneur T, Blanchard-Delaunay C, Godmer C, Puechal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L; French vasculitis Study Group 2014 Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771-1780.
51. Chen YX, Yu HJ, Ni LY, Zhang W, Xu YW, Ren H, Chen XN, Wang XL, Li X, Pan XX, Wang WM, Chen N 2007 Propylthiouracil-associated antineutrophil cytoplasmic autoantibody-positive vasculitis: retrospective study of 19 cases. J Rheumatol 34:2451-2456.
52. Gunton JE, Stiel J, Caterson RJ, McElduff A 1999 Clinical case seminar: antithyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab 84:13-16.
53. Batchelor N, Holley A 2006A fatal case of propylthiouracil-induced ANCA-positive vasculitis. Med-GenMed 8:10.
54. Poomthavorn P, Mahachoklertwattana P, Tapaneya-Olarn W, Chuansumrit A, Chunharas A 2002 Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease. J Med Assoc Thai 85:S1295-1301.
55. Mavrakanas TA, Bouatou Y, Samer C, de Seigneux S, Meyer P 2013 Carbimazole-induced ANCA-associated, crescentic glomerulonephritis: case report and literature review. Ren Fail 35:414-417.
56. Lee E, Hirouchi M, Hosokawa M, Sayo H, Kariya K 1988 Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol 37:2151-2153.
57. Akamizu T, Ozaki S, Hiratani H, Uesugi H, Sobajima J, Hataya Y, Kanamoto N, Saijo M, Hattori Y, Moriyama K, Ohmori K, Nakao 2002 Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity. Clin Exp Immunol 127:92-98.
58. Waldhauser L, Uetrecht J 1991 Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis. Drug Metab Dispos 19:354-359.
59. Haapala AM, Soppi E, Hyöty H, Mustonen J, Pasternack A 1991 Cross-reactivity between antibodies to thyroid microsomal antigens and myeloperoxidase. Lancet 337:803.
60. Heeringa P, Huugen D, Tervaert JW 2005 Anti-neutrophil cytoplasmic autoantibodies and leukocyte-endothelial interactions: a sticky connection Trends Immunol 26:561-564.
61. Nakazawa D, Tomaru U, Suzuki A, Masuda S, Hasegawa R, Kobayashi T 2012 Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxydase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3779-3787.
62. Yipp BG, Kubes P 2013 NETosis: how vital is it Blood 122:2784-2794.